Clinical trial
Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid…
NCT00256919 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00256919 |
|---|---|
| Title | Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA) |
| Official title | A Randomised, Placebo-controlled, Parallel Group Single Dose Study of GW856553 in Patients With Active RA to Investigate the C-Reactive Protein (CRP) Dose Response Relationship |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | GW856553 |
| Enrollment | 51 |
| Start date | Nov 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Nov 22, 2005 |
| Last update posted | Nov 5, 2012 |
| Countries | Bulgaria, Germany, Spain, Sweden, Ukraine |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: